Track your progress
Download the HD Chorea Treatment Tracking Guide to record when
AUSTEDO XR is taken and note any questions for your doctor.
Voucher and NEW Patient Copay Assistance information is now available here
Once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets contains the same active ingredient as twice-daily AUSTEDO (deutetrabenazine) tablets. Data on this page is based on twice-daily dosing. 1
People taking AUSTEDO saw more than
2x reduction in HD chorea vs placebo.*
*4.4-point improvement in people taking AUSTEDO vs 1.9 in people taking placebo based on Total Maximal Chorea (TMC) score. The TMC score is used to measure HD chorea movements in the face, mouth, trunk, both arms, and both legs.1,2
~3 years3†
†Mean TMC score changed minimally from Week 8 to Week 132 (or end of treatment).3
This was an open-label study, which is a drug trial in which all participants are aware of the drug being tested.4
Both doctors and people with HD chorea on AUSTEDO rated symptoms as “very much improved” or “much improved” at 12 weeks with AUSTEDO.
‡Treatment success is measured by perceived improvement in TMC score.
People taking AUSTEDO achieved greater improvement in the SF-36§ Physical Functioning Score at 12 weeks vs placebo.
See study details§SF-36=36-Item Short Form Health Survey assessing health-related quality of life.
AUSTEDO XR/AUSTEDO does not cure the cause of the involuntary movements and it does not
treat the other symptoms of HD, such as problems with thinking or emotions.1
Download the HD Chorea Treatment Tracking Guide to record when
AUSTEDO XR is taken and note any questions for your doctor.
Whether you're ready to start medication or planning
ahead, talking to a doctor is the first step.
The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?
References:
1. AUSTEDO® XR (deutetrabenazine) extended-release tablets/AUSTEDO® tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.
2. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.
3. Frank S, Testa CM, Stamler D, et al; Huntington Study Group ARC-HD Investigators. Long-term efficacy and safety of deutetrabenazine for chorea in Huntington's disease: results from the ARC-HD open-label study. Poster presented at: the 27th Annual Meeting of the Huntington Study Group (HSG); October 29-31, 2020.
4. Open-label. Merriam-Webster. Accessed March 13, 2023. https://www.merriam-webster.com/dictionary/open-label#medicalDictionary
5. Burgess JC, Davis B, Fogarty E, et al. Caregiver Guide for Mid to Late Stage Huntington's Disease: For Long-Term Care Facilities and In-Home Care Agencies. Huntington's Disease Society of America; 2014. Accessed February 27, 2023. http://hdsa.org/wp-content/uploads/2015/04/CaregiverGuide_Mid_Late_StageHD.pdf